Advanced search
Publication Cover
Expert Review of Vaccines Volume 2, 2003 - Issue 2
Submit an article Journal homepage
110
Views
20
CrossRef citations to date
0
Altmetric
Review

Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine

Rinaldo Zurbriggen Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Ian C Metcalfe Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Reinhard Glück Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
,
Jean-François Viret Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
&
Christian Moser Rinaldo Zurbriggen, PhD, Chief Scientific Officer, Pevion Biotech Ltd, Rehhagstrasse 79, CH-3018 Bern, Switzerland
Pages 295-304 | Published online: 09 Jan 2014

References

  • Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 23(4), 209–213 (2002).
  • McGhee JR, Czerkinsky C, Mestecky J. Mucosal vaccines: an overview. In: NIucosal Immunology 2nd Edition. Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR (Eds). Academic Press, London, UK, 741–757 (1999).
  • Jiang HR, Taylor N, Duncan L, Dick AD, Forrester JV. Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. BE j Ophthalmol 85(6), 739–744 (2001).
  • Collins LV, Eriksson K, Ulrich RG, Tarkowski A. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect. Immun. 70(5), 2282–2287 (2002).
  • Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coil heat-labile enterotoxins. Immunol Today20(11), 493–500 (1999).
  • Spangler, BD. Structure and function of cholera toxin and the related Escherichia coil heat-labile enterotoxin. Mcrobiol Rev 622–647 (1992).
  • Càrdenas-Freytag L, Cheng E, Mirza A. New approaches to mucosal immunization. Adv. Exp. Merl Biol. 473,319–337 (1999).
  • Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56(7), 1748–1753 (1988).
  • Jackson RJ, Fujihashi K, Xu Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: induction of systemic and mucosal B cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61,4272–4279 (1993).
  • Clements JD, Yancy RJ, Finkelstein RA. Properties of homogeneous heat-labile enterotoxin from Escherichia coil. Infect. Immun. 29,91–97 (1980).
  • Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coil heat labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6, 269–277 (1988).
  • van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunal 165(9), 4778–4782 (2000).
  • Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 2(7941), 899–901 (1975).
  • Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2 (2), 189–196 (2003).
  • Lambkin R, Oxford JS, Bossuyt S, Kelly LS, Viret JF, Gluck R. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome formulated influenza subunit vaccine. (Manuscript in preparation 2003).
  • de Bernardi di Valserra M, Zanasi A, Ragusa S, Gluck R, Herzog C. An open-label comparison of the immunogenicity, and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin. Ther. 24(1), 100–111 (2002).
  • Gluck U, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coil heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129-1132.
  • Gluck U, Gebbers JO, Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Viral 73(9), 7780–7786 (1999).
  • Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J. Infect. Dis. 146,780–890 (1982).
  • Herlocher ML, Elias S, Truscon R, Harrison S, Mindell D, Simon C, Monto AS. Ferrets as a transmission model for influenza: sequence changes in HAl of type A (H3N2) virus. J. Infect. Dis. 184, 542–546 (2001).
  • Fenton RJ, Clark A, Potter CW. Immunity to influenza in ferrets. XIV: comparative immunity following infection or immunisation with live or inactivated vaccine. Br Exp. Athol 62,297–307 (1981).
  • Abiko Y, Ikeda M, Hondo R. Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's palsy. Oral Neurotal 23(5), 779–783 (2002).
  • Schmutzhard E. Viral infections of the CNS with special emphasis on herpes simplex infections. J. Neural. 248(6), 469–477 (2001).
  • Steiner I, Mattan Y. Bell's palsy and herpes viruses: to (acyclo)vir or not to (acyclo)vir? J. Neural. Sci. 170(1), 19–23 (1999).
  • Furuta Y, Fukuda S, Chida E et al.. Reactivation of herpes simplex virus type 1 in patients with Bell's palsy. J. Med. Vital 54(3), 162–166 (1998).
  • Schirm J, Mulkens PS. Bell's palsy and herpes simplex virus. Acta Pathol Microbial. Immunal Scam/. 105(11), 815–823 (1997). Murakami S, Mizobuchi M, Nalcashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann. Intern Med 124(1 Pt 1), 27–30 (1996).
  • Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann.Intern. Med. 124(1 Pt 1), 27–30 (1996).
  • van den Broek ME, Muller U, Huang S, Zinkernagel RM, Aguet M. Immune defence in mice lacking type I and/or type II interferon receptors. Itufnunal Rev 148, 5–18 (1995).
  • Tashiro M, Pritzer E, Khoshnan MA et al.. Characterization of a pantropic variant of Sendai virus derived from a host range mutant. Virology 165(2), 577–583 (1988).
  • Tashiro M, Yamakawa M, Tobita K, Seto JT, Klenk HD, Rott R. Altered budding site of a pantropic mutant of Sendai virus, FI-R, in polarized epithelial cells. J. Viral 64(10), 4672–4677 (1990).
  • Honda N, Hato N, Takahashi H et al.. Pathophysiology of facial nerve paralysis induced by herpes simplex virus type 1 infection. Ann Oral Rhino]. Laryngol 111(7 Pt 1), 616–622 (2002).
  • Takahashi H, Hitsumoto Y, Honda N etal. Mouse model of Bell's palsy induced by reactivation of herpes simplex virus type 1. Neuropathol Exp. Neural. 60(6), 621–627 (2001).
  • Ishii K, Kurata T, Sata T, Hao MV, Nomura Y. An animal model of type-1 herpes simplex virus infection of facial nerve. Acta Otolaryngol Suppl 446, 157–164 (1988).
  • Hammond SA, Guebre-Xabier M, Yu J, Glenn GM. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy. Ctit. Rev. Ther. Drug Carrier Syst. 18(5), 503–526 (2001).

Websites

  • www.niaid.nih.gov/dmid/enteric/ intranasal.htm Website of the meeting 'Safety Evaluation of Toxin Adjuvants Delivered Intranasally' convened by the National Institute of Allergy and Infectious Diseases (NIAID) on July 9th, 2001.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.